3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Phase 1
1
Status
Completed
2
Unknown
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Other hematologic neoplasm
6
Lymphoid
4
Gastrointestinal
4
Genitourinary
3
Other solid neoplasm
2
Thoracic
1
Plasma cell
1
Other
1
Myeloid
1
CNS
1
Breast
1
Conditions
Prostatic Neoplasms
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Kidney Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Docetaxel
390
pembrolizumab
325
Prednisone
284
Gemcitabine
273
enzalutamide
254
Radiotherapy
251
Nivolumab
247
Magnetic Resonance Spectroscopy
247
Cisplatin
209
Abiraterone Acetate
197
Radiosurgery
184
Leuprolide
182
Sunitinib
169
Carboplatin
161
bicalutamide
148
Goserelin
145
Androgen Antagonists
142
Specimen Handling
138
Ipilimumab
128
Paclitaxel
125
Cyclophosphamide
116
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
110
Bevacizumab
109
Everolimus
107
apalutamide
98
cabozantinib
97
abiraterone
97
Sorafenib
97
atezolizumab
96
Radiation
89
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Interventional
×
Dosage Forms
×
Genitourinary
×
Clear all
NCT00913068
2021-10-04
TAP
Nova Scotia Health Authority
Phase NA
Completed
110 enrolled
5 charts
NCT01784757
2021-03-17
ARAFOR
Orion Corporation, Orion Pharma
Phase 1
Completed
30 enrolled
NCT04644432
2020-11-25
INDIGO
Herlev and Gentofte Hospital
Phase 2
Unknown
30 enrolled